Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers

Rinat Bernstein-Molho*, Yael Laitman, Shira Galper, Galia Jacobson, Ben Boursi, Einav Nili Gal-Yam, Bella Kaufman, Eitan Friedman, Orit Kaidar-Person

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Purpose: There is a paucity of data on the rates of ipsilateral breast tumor recurrence (IBTR) in BRCA1/2-associated breast cancer (BC). Scarcer yet are outcomes data in BRCA1/2 mutation carriers in the setting of newer mastectomy techniques, such as skin-sparing mastectomies (SSM) and nipple-sparing mastectomies (NSM).

Methods: Data were extracted from the medical records of BRCA1/2 carriers who were diagnosed with BC and treated at a single institution between 2006 and 2020. The data extracted included patient demographics, tumor characteristics, disease stage, surgical treatment, use of radiation therapy (RT), and disease outcome.

Results: Overall, 255 BC patients with BRCA1/2 germline mutations were identified. Of these, 128 (50.2%) underwent a mastectomy (SSM or NSM in 82% of them), 76 (59.4%) without postmastectomy RT (non-PMRT) and 52 (40.6%) with PMRT, whereas 127 (49.8%) elected for breast-conserving treatment (BCT). The non-PMRT group had earlier disease stages (82.3% were Tis and T1N0) compared with the PMRT and BCT groups (3.6% and 48.1%, respectively; P

Conclusions: BRCA1/2 mutation carriers treated with mastectomy without PMRT had higher rates of IBTR than those who underwent mastectomy and PMRT or BCT, despite earlier stages of disease. The safety of SSM/NSM should be evaluated in a prospective trial. (C) 2020 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)1332-1340
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number5
Publication statusPublished - 1 Apr 2021



Cite this